- Quebec
grant will help develop its cannabinoid products; ETST testing will
commence in 4Q2018 on formula patents aimed at preventing cancer and other
diseases
- ETST
will apply for trademark, finalize packaging for debut of medical device
designed to diminish sexually transmitted infections; women will be target
audience for this product
- Company
is focused on developing medical devices for the pharmaceutical and
nutraceutical fields and marketing its high-grade line of hemp cannabidiol
Earth Science Tech, Inc. (OTC: ETST) has established testing
dates for three of its cannabinoid-based (CBD) products. Funded by a grant from
Quebec, ETST is now prototyping three CBD patent formulas. A superfood edible
is expected to be ready for 4Q2018. The company is scheduled to begin in vitro
testing on its first batch of formulas in the summer of 2019, with a goal of
demonstrating the superior antioxidant properties and anti-proliferative
effects on breast cancer cells, it announced (http://ibn.fm/egQlU).
The goal of these products is to stop inflammation, maintain
quality of life, and help prevent cancer and other degenerative diseases. The
branding of these three products is in the planning stage.
ETST, a biotech company based in Doral, Florida, has
repositioned its line of full-spectrum CBD offerings. It also conducts R&D
for low cost, non-invasive medical devices as it concentrates on manufacturing,
marketing and distributing its cannabinoid products to the nutraceutical and
pharmaceutical markets.
Its MSN-2 medical device is in its final stage prior to the
launch of large-scale marketing. ETST is working with Montreal-based
Acceleration, Design et Innovation Inc. to aid in the preparation and
introduction. Final packaging is being designed to appeal to its target global
audience of women. The device is developed to prevent chlamydia and other
sexually transmitted infections.
“The official launch of this medical device is a little like
giving birth,” Dr. Michel Aube, CEO and chief science officer of ETST, stated
in a news release. “It will be unique in the marketplace and we are branding
this device globally. The commercial name will be announced soon, as we are in
the process of trademark protection for the logo and name.”
ETST holds several wholly owned subsidiaries. Cannabis
Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures
and distributes in the recreational sector. Earth Science Foundation, Inc. is
becoming a non-profit, accepting grants and donations to conduct additional
studies. Earth Science Pharmaceutical develops medical diagnostic tools and
vaccines. It also has subsidiary Canno Inno Laboratories Inc., a strategic
Montreal, Canada-based company formed to provide ETST with access to government
grants.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
